ASTRO 2022 | EXTEND: Combination therapy for oligometastatic prostate cancer

Chad Tang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, explains the rationale, study design, and results of the EXTEND trial (NCT03599765). Previous studies have shown that local therapy and hormone therapy can delay progression and improve overall survival (OS) for patients with metastatic cancer. The randomized, Phase II EXTEND trial investigated the use of radiotherapy and hormone therapy as a combination treatment for oligometastatic prostate cancer. The addition of radiotherapy alongside hormone therapy was found to improve progression-free survival (PFS). This would allow patients to have longer breaks from hormone therapy, which is known to have difficult side effects. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.